# Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma

> **NCT04553757** · — · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 100 (estimated)

## Conditions studied

- Brain Neoplasm
- Low Grade Glioma
- Seizure Disorder

## Interventions

- **OTHER:** Survey Administration

## Key facts

- **NCT ID:** NCT04553757
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-08
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04553757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04553757, "Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04553757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*